A Randomized Controlled Trial of the Efficacy and Safety of Lisdexamfetamine Dimesylate as Augmentation Therapy in Adults With Residual Symptoms of Major Depressive Disorder After Treatment With Escitalopram
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Evaluate the efficacy and safety of lisdexamfetamine dimesylate augmentation for major depressive disorder (MDD) in escitalopram nonremitters. METHOD: In this proof-of-concept study (conducted from July 2009-August 2010) with a prespecified critical α = .10, adults with nonpsychotic MDD (DSM-IV-TR criteria) and residual depressive symptoms (17-item Hamilton Depression Rating Scale score ≥ 4) after 8 weeks of open-label escitalopram were randomized to 6 weeks of lisdexamfetamine dimesylate (20-50 mg/d) or placebo augmentation. The primary endpoint, Montgomery-Asberg Depression Rating Scale (MADRS) total score change in escitalopram nonremitters (MADRS total score > 10) from week 8 (augmentation baseline) to week 14/end of study, was assessed using analysis of covariance, with last observation carried forward. RESULTS: For nonremitters (placebo, n = 64; lisdexamfetamine dimesylate, n = 65), the least squares (LS) mean (90% CI) treatment difference for MADRS total score reduction at week 14/end of study (-2.3 [-4.5 to -0.1]; P = .0902) met the prespecified criterion for lisdexamfetamine dimesylate superiority (adjusted effect size, -0.3); the number needed to treat for MADRS remission (MADRS total score ≤ 10) was 6.7. The LS mean treatment difference in remitters was not statistically significant (1.2 [-1.6 to 4.0]; P = .4726). Among randomized participants, 49.4% (42/85) receiving placebo and 60.2% (53/88) receiving lisdexamfetamine dimesylate had ≥ 1 treatment-emergent adverse event, the most frequent with lisdexamfetamine dimesylate being dry mouth and headache (both 11.4%). Mean (SD) vital sign and electrocardiogram changes (placebo vs lisdexamfetamine dimesylate) were 0.5 (8.98) versus 2.3 (9.04) mm Hg (systolic blood pressure), -1.0 (7.19) versus 0.9 (6.61) mm Hg (diastolic blood pressure), -0.4 (7.39) versus 4.8 (8.64) beats per minute (heart rate), and -1.6 (11.23) versus -4.9 (11.84) milliseconds (Fridericia-adjusted QTc). CONCLUSIONS: Lisdexamfetamine dimesylate augmentation reduced depressive symptoms in participants with inadequate escitalopram response. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00905424.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The safety profile was similar to that observed in studies of LDX in adults with ADHD (Weisler et al, 2009;Wigal et al, 2010) and MDD (Trivedi et al, 2013) and was consistent with those of other long-acting stimulants (Medori et al, 2008;Reimherr et al, 2007).”
From Lisdexamfetamine Dimesylate Augmentation in Adults With Persistent Executive Dysfunction After Partial or Full Remission of Major Depressive Disorder (2014) · cites this paper as Trivedi et al, 2013
In the citing paper
“There has been equivocal evidence for the efficacy of lisdexamfetamine dimesylate augmentation therapy in adults with MDD, with phase 2 studies reporting positive effects on residual depressive symptoms [137] and/or symptoms of executive dysfunction [138] but this was not replicated in phase 3 studies [139].”
From Adult ADHD and comorbid disorders: clinical implications of a dimensional approach (2017) · cites this paper as [137]
In the citing paper
“In one study, LDX augmentation of escitalopram met signal-detection criteria (prespecified 2-sided significance level α¼0.10) for significant reduction in mean Montgomery-Åsberg Depression Rating Scale (MADRS) total score versus placebo in escitalopram nonremitters (Trivedi et al., 2013).”
In the citing paper
“These findings do not support previously published findings of LDX augmentation for MDD based on 2 small phase 2 studies (Madhoo et al., 2014;Trivedi et al., 2013)”
In the citing paper
“The efficacy of LDX in MDD has been investigated in small, phase 2, randomized, double-blind, placebo-controlled studies in individuals with MDD who exhibited inadequate response to antidepressant monotherapy (Madhoo et al., 2014;Trivedi et al., 2013).”
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Still being checked.
Cited by
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Adult ADHD and comorbid disorders: clinical implications of a dimensional approach
Katzman, M. A., Bilkey, T. S., Chokka, P. R., Fallu, A., & Klassen, L. J. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1463-3 · Cited by 732
“There has been equivocal evidence for the efficacy of lisdexamfetamine dimesylate augmentation therapy in adults with MDD, with phase 2 studies reporting positive effects on residual depressive symptoms [137] and/or symptoms of executive dysfunction [138] but this was not replicated in phase 3 studies [139].”
BackgroundLam, R. W., Kennedy, S. H., McIntyre, R. S., & Khullar, A. (2014) · The Canadian Journal of Psychiatry · doi:10.1177/070674371405901206 · Cited by 438
Treatment-resistant depression: Definitions, review of the evidence, and algorithmic approach
McIntyre, R. S., Filteau, M.-J., Martin, L., Patry, S., Carvalho, A., Cha, D. S., Barakat, M., & Miguelez, M. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.10.043 · Cited by 421
McElroy, S. L., Hudson, J. I., Mitchell, J. E., Wilfley, D., Ferreira-Cornwell, M. C., Gao, J., Wang, J., Whitaker, T., Jonas, J., & Gasior, M. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.2162 · Cited by 322
Self-citationCognitive remission: a novel objective for the treatment of major depression?
Bortolato, B., Miskowiak, K. W., Köhler, C. A., Maes, M., Fernandes, B. S., Berk, M., & Carvalho, A. F. (2016) · BMC Medicine · doi:10.1186/s12916-016-0560-3 · Cited by 252
Nuñez, N. A., Joseph, B., Pahwa, M., Kumar, R., Resendez, M. G., Prokop, L. J., Veldic, M., Seshadri, A., Biernacka, J. M., Frye, M. A., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.134 · Cited by 215
Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications
Lucido, M. J., Bekhbat, M., Goldsmith, D. R., Treadway, M. T., Haroon, E., Felger, J. C., & Miller, A. H. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000043 · Cited by 138
Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder
Papakostas, G. I., & Ionescu, D. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.92 · Cited by 129
Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines
Taylor, R. W., Marwood, L., Oprea, E., DeAngel, V., Mather, S., Valentini, B., Zahn, R., Young, A. H., & Cleare, A. J. (2020) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa033 · Cited by 76
The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis
McIntyre, R. S., Lee, Y., Zhou, A. J., Rosenblat, J. D., Peters, E. M., Lam, R. W., Kennedy, S. H., Rong, C., & Jerrell, J. M. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000723 · Cited by 75
Madhoo, M., Keefe, R. S., Roth, R. M., Sambunaris, A., Wu, J., Trivedi, M. H., Anderson, C. S., & Lasser, R. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2013.334 · Cited by 74
Self-citationSalagre, E., Solé, B., Tomioka, Y., Fernandes, B. S., Hidalgo-Mazzei, D., Garriga, M., Jimenez, E., Sanchez-Moreno, J., Vieta, E., & Grande, I. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.06.034 · Cited by 71
Cognition as a target in major depression: new developments.
Solé, B., Jiménez, E., Martinez-Aran, A., & Vieta, E. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.12.004 · Cited by 68
Stimulants for depression: On the up and up?
Malhi, G. S., Byrow, Y., Bassett, D., Boyce, P., Hopwood, M., Lyndon, W., Mulder, R., Porter, R., Singh, A., & Murray, G. (2016) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867416634208 · Cited by 46
Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics
de Sousa, R. T., V. Zanetti, M., R. Brunoni, A., & Machado-Vieira, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630173522 · Cited by 43
“One proof-of-concept trial showed lisdexamfetamine dimesylate add-on to escitalopram to be more effective than placebo in treating depressive residual symptoms [83].”
BackgroundThe use of stimulant medications for non-core aspects of ADHD and in other disorders
Sinita, E., & Coghill, D. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.06.014 · Cited by 53
Antidepressant drug development: Focus on triple monoamine reuptake inhibition
Lane, R. M. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114553252 · Cited by 44
Novel pharmacologic treatment in acute binge eating disorder – role of lisdexamfetamine
Guerdjikova, A. I., Mori, N., Casuto, L. S., & McElroy, S. L. (2016) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s80881 · Cited by 40
“Preliminary data suggest LDX might be effective as adjunctive therapy to antipsychotics in adults with clinically stable schizophrenia,(14) to mood stabilizers in adults with bipolar depression,(15) and to antidepressants in adults with major depressive disorder.(16,17) LDX has also demonstrated potential to be an eff…”
Prada, P., Nicastro, R., Zimmermann, J., Hasler, R., Aubry, J., & Perroud, N. A. (2015) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-015-0165-2 · Cited by 44
A Review of Psychostimulants for Adults With Depression.
Pary, R., Scarff, J. R., Jijakli, A., TOBIAS, C. R., & Lippmann, S. (2015) · Europe PMC (PubMed Central) · Cited by 29
Williams, Z. J., Barnett, H., & Szigeti, B. (2026) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.4809 · Cited by 29
The Black Book of Psychotropic Dosing and Monitoring
DeBattista, C., & Schatzberg, A. F. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4493 · Cited by 25
D, M. F. M., Okame, T., Matsushima, Y., Perry, P. P., Weiller, E., & Baker, R. A. (2016) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw087 · Cited by 23
Richards, C., McIntyre, R. S., Weisler, R., Sambunaris, A., Brawman-Mintzer, O., Gao, J., Geibel, B., Dauphin, M., & Madhoo, M. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.07.006 · Cited by 20
Self-citationArousal Regulation in Affective Disorders
Hegerl, U., Sander, C., & Hensch, T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802456-0.00012-1 · Cited by 20
Epstein, I., Szpindel, I., & Katzman, M. A. (2014) · Psychiatry Research · doi:10.1016/s0165-1781(14)70003-4 · Cited by 23
Wake-Promoting Pharmacotherapy for Psychiatric Disorders
Dell’Osso, B. M., Dobrea, C., Cremaschi, L., Arici, C., & Altamura, A. C. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0524-2 · Cited by 19
The use of stimulants in depression: Results from a self-controlled register study
Rohde, C., Brink, P., Østergaard, S. D., & Nielsen, J. (2020) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867420924076 · Cited by 18
Richards, C., Iosifescu, D. V., Mago, R., Sarkis, E., Reynolds, J., Geibel, B., & Dauphin, M. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117722998 · Cited by 14
Self-citationThe Role of Stimulants in Late-Life Depression
Nelson, J. C. (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15030356 · Cited by 13
Primer for nutritionists: Managing the side effects of antidepressants
Tarleton, E. K., Kennedy, A. G., & Daley, C. J. A. (2016) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2016.05.004 · Cited by 15
Giacobbe, P., Rakita, U., Lam, R. W. M., Milev, R. V., Kennedy, S. H., & McIntyre, R. S. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.09.041 · Cited by 14
Hamilton scale and MADRS are interchangeable in meta-analyses but can disagree at trial level
Guizzaro, L., Morgan, D. D. V., Falco, A., & Gallo, C. (2020) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2020.04.022 · Cited by 11
Managing comorbid obesity and depression through clinical pharmacotherapies
McElroy, S. L., Guerdjikova, A. I., Mori, N. N., & Keck, P. E. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1198776 · Cited by 11
Janela, D., Jerónimo, J., Rema, J., Telles‐Correia, D., & Novais, F. (2023) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-023-00307-4 · Cited by 7
The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders
Roncero, C., & Alvarez, E. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.932691 · Cited by 7
Effect of amphetamines on blood pressure
Chan, M., Chan, J. J., & Wright, J. M. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007896.pub4 · Cited by 8
Kumar, J., Iezhitsa, I. N., & Agarwal, R. (2026) · Discover Neuroscience · doi:10.1186/s13064-026-00249-6 · Cited by 2
Thoughtful prescribing for patients with difficult-to-treat depression
Soubolsky, A., Visentin, J. D., & Crawley, A. (2023) · Canadian Family Physician · doi:10.46747/cfp.6911777 · Cited by 2
Use of psychostimulants in the management of treatment-resistant major depressive disorder
Pucci, S. L. (2025) · Mental Health Clinician · doi:10.9740/mhc.2025.08.197 · Cited by 1
Lisdexanfetamina em transtornos de humor: uma revisão sistemática
Martins-da-Silva, A. S., Mosconi, I. C., Cury, M. Á. A., & Palma, S. M. M. (2017) · Debates em Psiquiatria · doi:10.25118/2236-918x-7-5-2 · Cited by 1
Richards, C., Iosifescu, D. V., Mago, R., Sarkis, E. H., Geibel, B., Dauphin, M., McIntyre, R. S., Weisler, R. H., Brawman‐Mintzer, O., Gu, J., et al. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000897 · Cited by 2
Self-citationPrescription réfléchie pour les patients souffrant d’une dépression difficile à traiter
Soubolsky, A., Visentin, J. D., & Crawley, A. (2023) · Canadian Family Physician · doi:10.46747/cfp.6911e221 · Cited by 1
Inflammation and treatment resistance: Mechanisms and treatment implications
Miller, A. H., Lucido, M. J., Bekhbat, M., Mehta, N. D., Chen, X., Treadway, M. T., Felger, J. C., & Haroon, E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00015-3 · Cited by 1
Öztürk, C., Demırkol, S., Ünlü, M., Celık, T., & Iyısoy, A. (2014) · Angiology · doi:10.1177/0003319714523114 · Cited by 1
Psychostimulants in the treatment of depressive disorders
Ekinci, O., Ekinci, A. E., & Bolek, S. (2014) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.5455/cap.20141201111428
Lisdexamfetamindimesilat bei ADHS
Rottmann, K., Stegmann, B., & Haen, E. (2015) · NeuroTransmitter · doi:10.1007/s15016-015-0637-9
Current Treatments for Depression
Krystal, J. H., & Charney, D. S. (2017) · Oxford University Press eBooks · doi:10.1093/med/9780190681425.003.0031
Stimulants and Other Fast-Acting Drugs
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372997.as08
Stimulants and Other Fast-Acting Drugs
(2019) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615372300.as08
Unipolar Depression And Its Treatment
Stahl, S. M. (2022) · Cambridge University Press eBooks · doi:10.1017/9781009241595.012
Pavel, A. N., Dutu, I., Giurgiuca, A., & Matei, V. P. (2019) · Romanian Journal of Psychiatry & Psychotherapy · doi:10.37897/rjpp.2019.3.2
McElroy, S. L., Guerdjikova, A. I., & Romo‐Nava, F. (2024) · Cambridge University Press eBooks · doi:10.1017/9781108973922.014
Chapter 45. Psychostimulants and Wakefulness-Promoting Agents
DeBattista, C. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as45
Chapter 8. Stimulants and the Treatment of ADHD
(2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9798894551289.cd08
Current Treatments for Depression
Fava, M., & Krystal, J. H. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197640654.003.0034
Metadata
- Authors
- Trivedi, M. H., Cutler, A. J., Richards, C., Lasser, R., Geibel, B. B., Gao, J., Sambunaris, A., & Patkar, A. A.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Meridien Research (US)
- Duke University (US)
- Corresponding author
- Trivedi, Madhukar H.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2013-08-15
- Volume
- 74
- Issue
- 08
- Pages
- 802-809
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2052168906
- Cited by
- 58
- References
- 0
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2023: 3 · 2022: 3 · 2021: 1 · 2020: 3 · 2019: 3 · 2018: 1 · 2017: 7 · 2016: 9 · 2015: 9 · 2014: 8 · 2013: 2
- FWCI
- 6.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- lisdexamfetamine dimesylate, major depressive disorder, residual depressive symptoms, escitalopram, antidepressant augmentation, treatment-emergent adverse events, xerostomia, headache, vital signs, electrocardiographic changes, remission, treatment efficacy and safety, adults with depression, number needed to treat
- MeSH terms
- Lisdexamfetamine Dimesylate, Adolescent, Adult, Central Nervous System Stimulants, Depressive Disorder, Major, Major Depressive Disorder, Dextroamphetamine, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Personality Inventory, Psychometrics, Citalopram, Antidepressive Agents, Second-Generation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.